Shannon Sweeney
Nurse Practitioner, Surgery (Cardiac)Cards
About
Research
Publications
2025
Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis
Can M, Sweeney S, Allwood B, Dorman S, Cohen T, Menzies N. Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis. The Lancet Global Health 2025, 13: e1240-e1249. PMID: 40580989, PMCID: PMC12364304, DOI: 10.1016/s2214-109x(25)00114-7.Peer-Reviewed Original ResearchConceptsLifetime health lossPost-tuberculosis sequelaeHIV prevalence settingsProgressive lung damageLifetime health consequencesPrompt treatmentUS National InstitutesLung damageDelayed TreatmentPrevalence settingsNo treatmentLifetime health outcomesHealth benefitsLife expectancy lossConsequence of tuberculosisHealth effectsHigher mortality riskTuberculosis treatmentInitiation of tuberculosis treatmentLifetime disease burdenBenefits of prompt treatmentUS National Institutes of HealthDelayed initiationNational Institutes of HealthUntreated pulmonary tuberculosisSelecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach
Nemzoff C, Sweeney S, Baltussen R, Vassall A. Selecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach. International Journal Of Health Policy And Management 2025, 14: 1-9. PMID: 40767209, PMCID: PMC12089834, DOI: 10.34172/ijhpm.8562.Peer-Reviewed Original ResearchHealth benefits packageCost-effectiveness analysisHealth technology assessmentHealth benefit package designBenefit package designFollow-up surveyCost-effectiveCost-effectiveness analysis methodsCost-effectiveness modelHealth economicsLiterature reviewGlobal evidenceBenefit packageHealthPublic healthTechnology assessmentAssessment methodsSurvey of authorsExpert opinionMethod selectionPrioritization criteriaExtensive investmentLocal designAssess CEAssessment24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Sweeney S, Laurence Y, Berry C, Singh M, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso G, Jolivet P, Abdrasuliev T, Moe S, Aw P, Samieva N, Nyang'wa B. 24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. The Lancet Global Health 2025, 13: e355-e363. PMID: 39890235, DOI: 10.1016/s2214-109x(24)00467-4.Peer-Reviewed Original ResearchConceptsStandard of careRifampicin-resistant tuberculosisPatient-incurred costsHealth systemStandard-of-care regimensTreatment of rifampicin-resistant tuberculosisWeeks of follow-upAll-oral regimensReduce pill burdenImprove treatment efficacyTuberculosis treatment regimensCost-savingProbabilistic sensitivity analysesBurden of tuberculosisEconomic evaluationDegrees of cost savingsInpatient bed daysTrial-based evidenceEfficacy endpointCost dataRegimen groupPill burdenDrug regimensTreatment regimensUnfavourable outcomeFactors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.
Kim S, Can M, Agizew T, Auld A, Balcells M, Bjerrum S, Dheda K, Dorman S, Esmail A, Fielding K, Garcia-Basteiro A, Hanrahan C, Kebede W, Kohli M, Luetkemeyer A, Mita C, Reeve B, Silva D, Sweeney S, Theron G, Trajman A, Vassall A, Warren J, Yotebieng M, Cohen T, Menzies N. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis. PLOS Medicine 2025, 22: e1004502. PMID: 39804959, PMCID: PMC11729971, DOI: 10.1371/journal.pmed.1004502.Peer-Reviewed Original ResearchConceptsIndividual Patient Data Meta-AnalysisPatient data meta-analysisTreatment initiationData Meta-AnalysisBacteriological test resultsTB treatmentFactors associated with treatment initiationMultiple factors influence decisionsAssociated with treatment initiationTuberculosis treatment initiationMeta-analysisNegative test resultsPositive test resultsFactors influence decisionsHIV infectionPulmonary tuberculosisSmear microscopyNight sweatsClinical examinationMale sexClinical criteriaHierarchical Bayesian logistic regressionCohort studySystematic reviewTreatment decisions
2024
Estimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study
Keogh-Brown M, Sumner T, Sweeney S, Vassall A, Jensen H. Estimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study. PLOS Medicine 2024, 21: e1004491. PMID: 39666614, PMCID: PMC11637336, DOI: 10.1371/journal.pmed.1004491.Peer-Reviewed Original ResearchConceptsGross domestic productMacroeconomic burdenCumulative gross domestic productReturn to investmentHigh-income householdsLow-income householdsDomestic productEconomic growthReduction targetsIndian economyEconomic gainsInvestmentEconomic impactEconomyCountriesHouseholdsBurden of TBEconomic burdenDisease burdenFundingImpact of TBLarge healthCase detectionTB-related deathsProvisionImproving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation
Lewer D, Brown M, Burns A, Eastwood N, Gittins R, Holland A, Hope V, Ko A, Lewthwaite P, Morris A, Noctor A, Preston A, Scott J, Smith E, Sweeney S, Tilouche N, Wickremsinhe M, Harris M. Improving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation. NIHR Open Research 2024, 4: 10. PMID: 39568556, PMCID: PMC11576563, DOI: 10.3310/nihropenres.13534.2.Peer-Reviewed Original ResearchOpioid substitution therapyProcess evaluationPatient-directed dischargeAssociated with improved healthQualitative process evaluationHospital-based servicesHealth research projectsMixed-methods evaluationQuasi-experimental quantitative studyDifference-in-differences analysisMixed-methods studyOnline training moduleSubstitution therapyAdmitted to hospitalControl hospitalsAcute hospitalsImprove careOpioid withdrawalHospital cliniciansEmergency readmissionIllicit opioidsHospital staffQuantitative studyFocus groupsClinical guidelinesAfrica Health Research Institute (AHRI) Household Contact study: a study protocol, statistical analysis and modelling plan
Khan P, Govender I, McCreesh N, Sweeney S, Sithole M, Ording-Jespersen G, Buthelezi X, Houben R, Baisley K, Smit T, Wong E, Hanekom W, White R, Vassall A, Fielding K, Grant A. Africa Health Research Institute (AHRI) Household Contact study: a study protocol, statistical analysis and modelling plan. Wellcome Open Research 2024, 9: 622. DOI: 10.12688/wellcomeopenres.22974.1.Peer-Reviewed Original ResearchAfrica Health Research InstituteQuantiFERON-TB Gold PlusHealth systemAntiretroviral treatmentReport symptomsCost-effectiveness of interventionsAntiretroviral treatment careRoutine health servicesDemographic surveillance areaTuberculosis case findingHealth Research InstituteM. tuberculosis transmissionChild household contactsPotential epidemiological impactTuberculosis screening strategiesHealthcare utilisationHIV testingHealth facilitiesPulmonary tuberculosisHealth servicesSymptom screeningCase findingCost-effectiveTuberculosis screeningEffects of antiretroviral treatmentUncertainty in tuberculosis clinical decision-making: An umbrella review with systematic methods and thematic analysis
Basile F, Sweeney S, Singh M, Bijker E, Cohen T, Menzies N, Vassall A, Indravudh P. Uncertainty in tuberculosis clinical decision-making: An umbrella review with systematic methods and thematic analysis. PLOS Global Public Health 2024, 4: e0003429. PMID: 39042611, PMCID: PMC11265660, DOI: 10.1371/journal.pgph.0003429.Peer-Reviewed Original ResearchUmbrella reviewClinical decision-makingHealthcare system levelQualitative evidence synthesisBarriers to treatmentScarcity of healthcare resourcesTuberculosis knowledgeClinicians' attitudesCommon barriersResource-limited settingsHealth careHealthcare settingsClinical encountersEvidence synthesisInfluence clinical decisionsThematic analysisHealthcare resourcesDiagnostic test characteristicsStudy designSystematic reviewMeta-analysesNegative test resultsMulti-level modelProvidersDecision-makingUnit costs and cost-effectiveness of a device to improve TB treatment adherence in China
Sweeney S, Fielding K, Liu X, Thompson J, Dong H, Jiang S, Zhao Y, Huan S, Vassall A. Unit costs and cost-effectiveness of a device to improve TB treatment adherence in China. IJTLD OPEN 2024, 1: 299-305. PMID: 39035432, PMCID: PMC11257087, DOI: 10.5588/ijtldopen.23.0451.Peer-Reviewed Original ResearchIntervention cost-effectivenessHealth facility levelIncremental cost-effectiveness ratioProbabilistic sensitivity analysesTB treatment adherenceCluster-randomised superiority trialImprove treatment outcomesIncremental cost-effectivenessCost-effectiveness ratioIncremental costCost-effectiveDiscount rateUnit cost dataTreatment adherenceFacility levelLack of evidenceTreatment outcomesImprove adherenceDigital adherence technologiesEnhance patient managementScenario analysisSocietal perspectiveSuperiority trialStandard of careAdherence technologiesEconomic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis
Ryckman T, Schumacher S, Lienhardt C, Sweeney S, Dowdy D, Mirzayev F, Kendall E. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. The Lancet Global Health 2024, 12: e995-e1004. PMID: 38762299, PMCID: PMC11126367, DOI: 10.1016/s2214-109x(24)00088-3.Peer-Reviewed Original ResearchConceptsRifampin-resistant tuberculosisRifampin-susceptible tuberculosisMedium-term costsTuberculosis treatmentRifampin susceptibilityTuberculosis regimensStandard-of-care regimensCost-effective priceEstimated pricePrice thresholdsPriceDrug costsCost-neutralNovel drug combinationsStandard-of-careSouth AfricaTuberculosis treatment regimensEconomic implicationsStandard of carePatient-borne costsHigh-burden countriesCohort of adultsDecision-analytic modelShorter regimensNovel regimens